For the prevention of conventional AD prior to the initiation of the AβPP-independent iAβ production pathway, the targeted degradation of iAβ via the activation of BACE1 and/or BACE2 would be sufficient on its own. The gene discussed is BACE2; the disease is Alzheimer disease.